Nicholas J. Silvestri

Treatment patterns of oral corticosteroid and nonsteroidal immunosuppressant therapy and clinical outcomes in US patients receiving ravulizumab or eculizumab for generalized myasthenia gravis

Svetlana Faktorovich, Nicholas J. Silvestri, Justin Lee, Karen S. Yee et autres

Comprehensive Care Goals in Myasthenia Gravis

Pushpa Narayanaswami, Renato Mantegazza, Carolina Barnett, Elena Cortés‐Vicente et autres

BACKGROUND AND OBJECTIVES: Goals for comprehensive care are important in the management of individualized treatment for patients with myasthenia gravis (MG), a disease with variable presentation and degrees of severity. Yet there is limited guidance on how comprehensive care should be achieved …

us, it, ca, es, no, pl, gb, de, fr, jp (code pays fourni par la source)

Oral Corticosteroid and Nonsteroidal Immunosuppressant Therapy Use in Patients with Myasthenia Gravis Receiving Ravulizumab, Eculizumab, or Efgartigimod in the USA

Francesco Saccà, Justin Lee, Karen Yee, Nicholas J. Silvestri et autres

INTRODUCTION: Oral corticosteroids (OCSs) and nonsteroidal immunosuppressant therapies (NSISTs) remain widely used for the clinical management of patients with generalized myasthenia gravis (gMG), despite well-documented risks. Newer targeted biologic therapies have demonstrated concomitant immunosuppressant therapy reduction; however, long-term comparative real-world evidence remains …

it, us (code pays fourni par la source)

Survival Outcomes of Medicare‐Covered Elderly US Population With Myasthenia Gravis

Yuebing Li, David Bruckman, Jesse D. Schold, Benjamin Claytor et autres

INTRODUCTION/AIM: Survival outcomes have been inadequately studied among people with myasthenia gravis (MG) in the United States (US). We examined the impact of MG and comorbid conditions on longevity. METHODS: We performed a longitudinal study using Medicare claims data (2006-2019). Incident MG …

us (code pays fourni par la source)

MSR115 Prediction of Myasthenia Gravis (MG) Crisis Events by a Machine Learning (ML) Algorithm

Nicholas Streicher, Karen S. Yee, Justin Lee, Nicholas J. Silvestri

us (code pays fourni par la source)

What Patients Don’t Say and Physicians Don’t Ask: A Needs Assessment in Myasthenia Gravis Integrating Patient and Healthcare Professional Perspectives

C. Acosta, Ivo Vlaev, Alexis Rodriguez, Allison Foss et autres

INTRODUCTION: Myasthenia gravis (MG) is a rare, autoimmune neuromuscular disease characterized by unpredictable fluctuating muscle weakness. This unpredictability makes effective patient-healthcare professional (HCP) dialogue essential for optimal diagnosis and management, with communication as a key component of shared decision-making (SDM). We designed …

de, gb, us, dk, be, ie (code pays fourni par la source)

Design of a Digital Solution to Improve Myasthenia Gravis Patient Symptom Tracking in Routine Clinical Care (P8-11.032)

Srikanth Muppidi, Joshua Alpers, Ashley Anderson, Nicholas J. Silvestri et autres

Determine design requirements for a digital tool utilizing validated patient-reported outcomes (PROs) to improve symptom tracking and communication between patients with myasthenia gravis (MG) and healthcare practitioners (HCPs) in routine practice.

us, it, be (code pays fourni par la source)

Survival Outcomes of Medicare-covered Elderly US Population with Myasthenia Gravis (P6-11.032)

Yuebing Li, David Bruckman, Jesse D. Schold, Benjamin Claytor et autres

We performed a retrospective longitudinal study using Medicare claims data (2006 – 2019).

us (code pays fourni par la source)

Real-world Treatment Patterns Among Patients with Generalized Myasthenia Gravis (P6-11.027)

Kavita Grover, Kavita Gandhi, Martin Cloutier, Geoffroy Coteur et autres

To evaluate real-world treatment patterns and myasthenia gravis (MG)-related clinical events among patients with generalized MG (gMG) in the US.

us, be (code pays fourni par la source)

Large-scale profiling of antibody reactivity to glycolipids in patients with Guillain-Barré syndrome

Robin C.M. Thomma, Susan K. Halstead, L.C. de Koning, Evelin E J A Wiegers et autres

Guillain-Barré syndrome is an acute polyradiculoneuropathy in which preceding infections often elicit the production of antibodies that target peripheral nerve antigens, principally gangliosides. Anti-ganglioside antibodies are thought to play a key role in the clinical diversity of the disease and can be …

nl, gb, dk, it, fr, ar, Afrique du Sud, be, de, es, gr, ca, us, au, at, bd, jp, uy, ch, my (code pays fourni par la source)

Individualized Dosing of Efgartigimod in Patients With Generalized Myasthenia Gravis: Clinical Experience at a Single Center

Nicholas J. Silvestri

INTRODUCTION/AIMS: Neonatal Fc receptor (FcRn) inhibitors represent a promising treatment option for patients with generalized myasthenia gravis (gMG); however, data on clinical use are limited. The aim of this report is to describe one center's approach to efgartigimod dosing in patients with …

us (code pays fourni par la source)

Appropriate use of steroids for patients with generalized Myasthenia Gravis: an international Delphi study

Heinz Wiendl, Hiroyuki Murai, Pushpa Narayanaswami, Francesco Saccà et autres

Background: Oral corticosteroids (OCS) are commonly used in the management of autoimmune Myasthenia Gravis (MG), often in high doses for prolonged periods. Exposure to OCS is associated with significant and cumulative adverse effects. There is currently no universal consensus on the approach …

de, jp, us, it (code pays fourni par la source)